Back to top
more

Lantheus (LNTH)

(Delayed Data from NSDQ)

$123.42 USD

123.42
2,412,419

-0.20 (-0.16%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $123.30 -0.12 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Investors Must Hold on to Centene (CNC) Stock Now

by Zacks Equity Research

Centene (CNC) is expected to benefit from expanding margins in the Marketplace business, contract wins in Medicaid, and improved Medicare Advantage Star ratings.

Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS

by Zacks Equity Research

Alcon (ALC) gets FDA 510(k) clearance for its Unity VCS and Unity CS. The company will start a thorough program to get real-world feedback before the systems' commercial launch in 2025.

Inspira (IINN) Unveils Business Targets for 2024-25

by Zacks Equity Research

Inspira (IINN) discloses business goals for 2024-25 with the rapid promotion of INSPIRA ART100 and the development of INSPIRA ART (Gen 2).

Zacks Industry Outlook Highlights Boston Scientific, ResMed, Lantheus and Haemonetics

by Zacks Equity Research

Boston Scientific, ResMed, Lantheus and Haemonetics are part of the Zacks Industry Outlook article.

New Strong Buy Stocks for June 21st

by Zacks Equity Research

ASYS, LAUR, ESLT, LNTH and LMAT have been added to the Zacks Rank #1 (Strong Buy) List on June 21, 2024.

Best Value Stocks to Buy for June 21st

by Zacks Equity Research

LAUR, ESLT and LNTH made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 21, 2024.

Thermo Fisher (TMO) Unveils New Research Laboratory in WI

by Zacks Equity Research

Thermo Fisher (TMO) announces a new 72,500-square-foot clinical research laboratory building at its good manufacturing practices lab in Middleton, WI

Haemonetics (HAE) Expands VASCADE Line With New Limited Launch

by Zacks Equity Research

Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device.

Indrajit Bandyopadhyay headshot

4 Medical Product Stocks to Buy From a Recovering Industry

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.

Lantheus Holdings (LNTH) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Lantheus Holdings (LNTH) concluded the recent trading session at $81.13, signifying a -1.82% move from its prior day's close.

Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Compelling Reasons to Hold on to Cigna (CI) Stock for Now

by Zacks Equity Research

Cigna (CI) remains well-poised for growth on the back of improved pharmacy revenues in its Evernorth unit. Solid cash-generating abilities also enable it to tactically deploy capital.

Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Castle Biosciences, Inc. (CSTL) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Shaun Pruitt headshot

Don't Overlook These Highly Ranked Medical Stocks as Markets Rise

by Shaun Pruitt

With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.

New Strong Buy Stocks for June 12th

by Zacks Equity Research

RDNT, ESLT, CLS, LNTH and ASBFY have been added to the Zacks Rank #1 (Strong Buy) List on June 12, 2024.

Humana's (HUM) CenterWell Sets Foot in Asheville With New Centers

by Zacks Equity Research

Humana's (HUM) CenterWell Senior Primary Care announces the opening of two centers in Asheville, thus enhancing access to high-quality healthcare services and driving revenues of the CenterWell unit.

Lantheus Holdings (LNTH) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

In the most recent trading session, Lantheus Holdings (LNTH) closed at $79.28, indicating a -0.78% shift from the previous trading day.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

National Vision (EYE) Down 4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Moumi Mondal headshot

Buy These 3 Beaten-Down MedTech Stocks for a Turnaround Soon

by Moumi Mondal

Investing in beaten-down stocks like OPCH, LNTH and HOLX can be profitable for investors in the long term.

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks

by Zacks Equity Research

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Lantheus Holdings (LNTH) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Lantheus Holdings (LNTH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Best Momentum Stocks to Buy for May 31st

by Zacks Equity Research

MNSO, LNTH and LXFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 31, 2023.

Tenet Healthcare (THC) Gains 89% in a Year: More Room to Run?

by Zacks Equity Research

Tenet Healthcare (THC) is well-poised to gain from improved volumes, expansion of specialty services, streamlining operations and operational efficiency.